carboxymethyl-migrastatin core ether

Carboxymethyl-migrastatin core ether (CME) is a synthetic small-molecule analog of the natural product migrastatin, developed by Samuel J. Danishefsky and colleagues at Memorial Sloan-Kettering Cancer Center and Columbia University. Designed to overcome the pharmacological limitations of migrastatin, CME exhibits improved solubility and metabolic stability while maintaining potent anti-metastatic properties. Its mechanism of action involves the inhibition of tumor cell migration by targeting actin-bundling proteins, specifically fascin-1, and interfering with Rac-mediated signaling pathways. This disruption prevents the formation of cytoskeletal structures necessary for cell motility, such as lamellipodia and filopodia. Preclinical studies have demonstrated that CME significantly reduces metastatic spread in models of small-cell lung cancer, breast cancer, and colorectal carcinoma without affecting the growth of the primary tumor.

Other names

carboxymethyl-migrastatin core ethermigrastatin core ether derivative